-
Product Insights
Private Dev/ Silverback Dev – Gramercy Park Condominium Tower – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our Private Dev/ Silverback Dev - Gramercy Park Condominium Tower - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
Bizzi & Ptnrs / Silverback Dev – New River Central Mixed-Use Complex – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our Bizzi & Ptnrs / Silverback Dev - New River Central Mixed-Use Complex - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Company Profile
ARS Pharmaceuticals Inc – Company Profile
ARS Pharmaceuticals Inc (ARS Pharmaceuticals), formerly Silverback Therapeutics Inc, focuses on the discovery, development and commercialization of medicines for the treatment of chronic viral infections, cancer, and other serious diseases. The company is advancing SBT6050 for breast cancer, gastric cancer, and non-small cell lung cancer (NSCLC), SBT6290 for bladder cancer, triple-negative breast cancer (TNBC), and head and neck (H&N) cancer; and SBT8230 for chronic hepatitis B virus. ARS Pharmaceuticals is also advancing pre-clinical candidates for the treatment of solid tumors...
Add to Basket -
Product Insights
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain. The Hepatitis B pipeline market research report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Toll-like receptor 8 is a protein encoded by the TLR8 gene. It acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. The Toll Like Receptor 8 (CD288 or TLR8) Development market research report provides an in-depth analysis of Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of...